TABLE 5.
The causal prophylaxis of DQ HME formulations in female NIH-Swiss micea
| Formulations or compounds | Dose (mg/kg) | n | Day 12 |
Day 60 |
||
|---|---|---|---|---|---|---|
| Infected | Protected rate | Survived | Survival rate | |||
| Saline | 0 | 5 | 5 | 0 | 0 | 0 |
| PQ | 20 | 5 | 2 | 60 | 4 | 80 |
| F2(DQ) | 5 | 5 | 2 | 60 | 4 | 80 |
| F8(DQ) | 5 | 5 | 3 | 40 | 5 | 100 |
| F9(DQ) | 5 | 5 | 2 | 60 | 5 | 100 |
| F11(DQ) | 5 | 5 | 1 | 80 | 5 | 100 |
| F12(DQ) | 5 | 5 | 1 | 80 | 4 | 80 |
| F15(DQ) | 5 | 5 | 1 | 80 | 5 | 100 |
a
Selected DQ HME formulations (DQ dose of 5 mg/kg) were given to mice by intragastric gavage at day 1 (the day before sporozoite [SPZ] inoculation), day 0 (the same day), and day 1 (the day after) of SPZ inoculation. Blood smears from tail vein were examined at different days (days 7, 12, and 19). Survival rates were summarized at day 60.